Overview

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
To estimate the safety and tolerability of 250 mg ZD1839 given concurrently with 3D-CRT in patients with non-metastatic prostate cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gefitinib